Qinghai Zhao, Ph.D., is the Chief Manufacturing Officer of Adagene. He has over 25 years of drug development experience in the biopharmaceutical industry. Most recently, he served as the Vice President of Technical Development and Manufacturing at Forty Seven Inc., an immunology company acquired by Gilead in early 2020. There, he was responsible for CMC development and clinical supply management for a number of programs, including magrolimab. Prior to Forty Seven, Dr. Zhao was the Vice President of CMC and Manufacturing at AnaptysBio. Prior to that, he held leadership positions in managing biological process development and manufacturing, including Head of CMC at NGM Bio and Director of CMC management at Teva Biopharmaceuticals USA, where he led multiple CMC programs including reslizumab, which was approved by the FDA for commercial manufacturing in 2016. In his early career in China, he served as Head of Plasma Protein Therapeutics R/D at Shanghai Institute of Biological Products. Dr. Zhao earned his Ph.D. in life sciences from Uppsala University, his MS in biochemistry from Fudan University (Shanghai Medical University) and BE degree in biochemistry from East China University of Science and Technology.
Dr. Guizhong Liu, Head of biology and pharmacology in Adagene, leading the preclinical pharmacology and toxicology research for product development. Dr. Liu has over 15-year experience in drug discovery and development, both in small molecule kinase inhibitors and large molecule antibodies in oncology and immunology field. Prior to joining Adagene, Dr. Liu served as head of molecular cancer biology in CrownBio, where he was in charge of contracted research projects from various big pharma and small biotech companies, as well as leading the novel drug development programs from biology and pharmacology side. Prior to CrownBio, Dr. Liu had worked as Assistant Professor in the department of oncological sciences at Mount Sinai School of Medicine, with over 40 peer-reviewed publications in high-profile journals. Dr. Liu completed his postdoctoral research with Dr. Stuart Aaronson at Mount Sinai School of Medicine, received his Ph.D. from Peking Union Medical College, and obtained his B.S. and M.S. degrees at Beijing Normal University.
Ron (Yuren) Wang, Ph.D., is the Head of Portfolio Management for Adagene. Dr. Wang has over 20 years of drug discovery and development experience in large pharmaceutical and biotech companies, making significant contributions to the scientific development of various drugs. During his career, he has led or integrally participated in over 20 projects from novel target validation, drug discovery, and biomarker strategy to preclinical candidates.
Prior to joining Adagene, Dr. Wang served as Vice President of R&D research for Jemincare Therapeutics (USA), responsible for the scientific evaluation of projects, in-licensing and portfolio management. Before that, he was the Senior Director of Business Development in Reaction Biology Corporation (RBC), where he led custom service in drug discovery of protein kinases and cancer epigenetic areas. Dr. Wang was also a project leader in metabolic disease of Bristol Myers Squibb and Wyeth Neuroscience Research (now owned by Pfizer).
Dr. Wang received his Ph.D. in molecular and cellular biology from the University of Pennsylvania and completed his postdoctoral training in molecular pharmacology at Dr. David Manning’s laboratory at the University of Pennsylvania. He has published more than 30 research papers in peer-reviewed journals and is the inventor of multiple patents.
Alexander Goergen is the Executive Director of Business Development and Head of Licensing at Adagene. He has extensive experience in partnering and strategic planning, and is focused on fostering synergistic relationships in the pharmaceutical and biotech industry for the purpose of advancing human healthcare. Prior to joining Adagene, Alexander spent several years in business development for Catalent Pharma Solutions Biologics Division.
Alexander completed many licensing, manufacturing, and cell line development programs both domestically and internationally. Alexander was also in charge of managing a relationship with one of Catalent’s key global strategic accounts prior to joining Adagene. Before joining Catalent, Alexander worked in various roles at the International AIDS Vaccine Initiative, Covance , and TRC.
Alexander holds an M.S. from the School of Medicine and Public Health at the University of Wisconsin-Madison. He completed his undergraduate work at Lafayette College.
Kristine (Xiaohong) She is the Vice President of Operations at Adagene. She has over 20 years of laboratory experience in America’s most renowned laboratories, completing multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran’s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science and Biotechnology, among many other notable publications. From these projects, Ms. She has gained extensive operational and management experience, as she often led her coworkers in laboratory and experimental work.
Ms. She received her M.S. from the Institute of Microbiology of the Chinese Academy of Sciences, and her B.S.from Wuhan University.
Yan Li is the Vice President of Bioinformatics and Information Technology at Adagene. She has over 15 years of experience in software development, with more than 10 years focused on the development of informatics software tools for antibody library design and analysis.
Prior to joining Adagene, Ms. Li served as the Senior Software Engineer and Applications Scientist at Abmaxis from November 2001 to May 2006. She developed the software platform for the company’s proprietary AISIM technology, and designed many antibody libraries for in-house pipeline development and business partners. Following the acquisition of Abmaxis by Merck & Co, Ms. Li worked at Merck from May 2006 to December 2010. She received the Merck Award for Excellence in “Innovative Technologies” with the team, and a Special Award for her contribution.
Before her time at Abmaxis, Ms. Li served as a software engineer at Easyware Software, and also as a system analyst and product manager at Singapore Telecom.
Ms. Li received her BSE in information science from East China University of Science and Technology, and her M.B.A. from Santa Clara University with Beta Gamma Sigma honor. She is an inventor of many US and international patents.
JC Xu, M.D., Ph.D., is the Chief Scientific Officer of Adagene. Dr. Xu has more than 20 years of experience in oncology drug discovery and development and more than 4 years of experience in business development, strategy, and operations in the U.S. biopharmaceutical industry.
Prior to joining Adagene, Dr. Xu was head of R&ED China Strategy at Celgene (now Bristol Myers Squibb). Prior to that, Dr. Xu was Director of Strategy & Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals. She was instrumental in the successful acquisition of Quanticel by Celgene. Prior to Quanticel, Dr. Xu worked in leadership roles at a number of biopharmaceutical companies, both large and small, including Pfizer, Amgen, and Corixa.
Dr. Xu received her M.D. from Beijing Medical University (now Peking University Health Science Center) and her Ph.D. in immunology from University of Alabama at Birmingham. She completed her post-doctoral training at DNAX Research Institute (now Merck Palo Alto). She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.
Raymond Tam Man Kin (“Mr. Tam”) is the Chief Financial Officer of Adagene. He has over 20 years of management experience in finance and banking across Asia Pacific.
Prior to Adagene, Mr. Tam served as Chief Financial Officer of different corporations including AgenTus Therapeutics, Inc., Beijing Gas Blue Sky Holdings Limited (a company listed on the Stock Exchange of Hong Kong), and China Regenerative Medicine International Limited (a company listed on the Stock Exchange of Hong Kong). Mr. Tam also served as Project Director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited, both of which are Australian mining companies. Further, he held various management positions with J.P. Morgan and HSBC from 1999 to 2010.
Mr. Tam obtained an Executive Master of Business Administration degree from the University of Western Ontario in Canada in 2005, a Master of Practising Accounting degree from the Monash University in Australia in 2001 and a Bachelor of Civil & Resources Engineering (with First Class Honors) degree from the University of Auckland in New Zealand in 1998.
Felix (Fangyong) Du, Ph.D., is the Chief Technology Officer of Adagene. Dr. Du has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.
Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After Affomix was acquired by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.
Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. from Peking University.
Hua Gong, M.D., Ph.D., is the Chief Operating Officer and Head of Clinical Development and Precision Medicine at Adagene. She has more than 20 years of experience in drug discovery and development, particularly in personalized medicine. Dr. Gong joined Adagene from Novartis Navigate Biopharma where she served as Senior Director, Head of Genomics Biomarker Department. She directly contributed to the U.S. Food and Drug Administration approvals of seven oncology drugs since 2013: Tabrecta™ (capmatinib), Piqray® (alpelisib), Tafinlar® (dabrafenib) + Mekinist® (trametinib) for NSCLC, Kisqali® (ribociclib) , Kymriah® (tisagenlecleucel) and Zykadia® (ceritinib).
Prior to Novartis, she was Executive Director of IVD & CDx at Premier Research Group, where she effectively enabled oncology development programs of their pharmaceutical partners by providing precision medicine solutions. At Prometheus Therapeutics & Diagnostics, Dr. Gong was Associate Director of the Clinical Development Department, where she was responsible for overseeing multiple clinical studies. She successfully contributed to the expansion of Proleukin clinical applications. Additionally, Dr. Gong worked at Pfizer for over 10 years in a variety of positions of increasing responsibility. In her last position at Pfizer, Dr. Gong managed a multi-disciplinary team including in-vitro/vivo biology, PDM, drug safety and biomarker research groups. She was a key contributor to two drugs that entered clinical development.
Dr. Gong received her medical training from An Hui Medical University, her M.S. from Sun Yat-Sen University of Medical Sciences and her Ph.D. in cancer biology from Wayne State University.